Skip to main content
Clinical Trials/NCT00957346
NCT00957346
Terminated
Phase 3

Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14-21 Weeks LMP): A Randomized-controlled Double-blinded Trial

Gynuity Health Projects1 site in 1 country20 target enrollmentFebruary 2011

Overview

Phase
Phase 3
Intervention
Mifepristone+misoprostol
Conditions
Abortion, Induced
Sponsor
Gynuity Health Projects
Enrollment
20
Locations
1
Primary Endpoint
Rate of successful abortion: defined as complete evacuation of uterus using study drug without recourse to any additional intervention.
Status
Terminated
Last Updated
14 years ago

Overview

Brief Summary

The primary goal of this study is to determine the clinical advantage of pre-treatment with mifepristone in second trimester misoprostol induction abortion. This will be a randomized controlled double-blinded trial of 20 women comparing misoprostol alone to mifepristone plus misoprostol for second trimester (14-21 weeks' LMP) medical abortion.

Registry
clinicaltrials.gov
Start Date
February 2011
End Date
January 2012
Last Updated
14 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
Gynuity Health Projects
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Meet legal criteria to obtain abortion
  • Present with closed cervical os and no vaginal bleeding
  • Live fetus at time of presentation for service
  • Have no contraindications to study procedures, according to provider
  • Be able to consent to procedure, either by reading consent document or by having consent document read to her
  • Be willing to follow study procedures

Exclusion Criteria

  • Known previous transmural uterine incision
  • Known allergy to mifepristone or misoprostol/prostaglandin or other contraindications to the use of mifepristone or misoprostol
  • Any contraindications to vaginal delivery, including placenta previa
  • Presentation in active labor (defined as moderate to severe contractions every 10 minutes or less)

Arms & Interventions

Mifepristone + Misoprostol

200 mg mifepristone followed by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.

Intervention: Mifepristone+misoprostol

Misoprostol

Placebo resembling 200mcg mifepristone followed by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses

Intervention: Placebo+Misoprostol

Outcomes

Primary Outcomes

Rate of successful abortion: defined as complete evacuation of uterus using study drug without recourse to any additional intervention.

Time Frame: every 3 hours

Induction-to-abortion interval: defined as time elapsed between administration of the first misoprostol dose until expulsion of the fetus; approximately 10-24 hours.

Time Frame: 48 hours

Secondary Outcomes

  • Provision of additional interventions to manage excessive blood loss.(Within 30 days of mifepristone administration.)
  • Total dose of misoprostol.(Assessed at time of complete abortion with study drug alone or when total maximum dose given: approximately 10-24 hours after first dose of misoprostol administration.)
  • Any heavy bleeding, uterine rupture, or infection requiring additional treatment(Within 30 days of mifepristone administration.)
  • Pain experienced by the woman(Assessed during exit interview: approximately 48 hours after first dose of misoprostol administration.)
  • Women's acceptability of the assigned method(Assessed during exit interview: approximately 48 hours after first dose of misoprostol administration.)

Study Sites (1)

Loading locations...

Similar Trials